Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 84.21 percent increase over losses of $(0.57) per share from
Silence Therapeutics lost less money than experts thought it would this quarter, which is good news. When a company that's still losing money does better than people expected, it shows the business is moving in a better direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.